Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
about
Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validationPredictive value of tissue inhibitor of metalloproteinases-1 and carcinoembryonic antigen plasma levels in response to chemotherapy in patients with metastatic colorectal cancerA marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.
P2860
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@ast
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@en
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@nl
type
label
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@ast
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@en
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@nl
prefLabel
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@ast
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@en
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@nl
P2860
P1476
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
@en
P2093
Potjana Jitawatanarat
P2860
P304
P356
10.3978/J.ISSN.2078-6891.2013.008
P577
2013-06-01T00:00:00Z